Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

SUMMARY: Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models. Methods We conducted a Phase I study of idasanutlin (microprecipitate bulk powder formulation) to determine the maximum t...

Descripción completa

Detalles Bibliográficos
Autores principales: Italiano, Antoine, Miller, Wilson H., Blay, Jean-Yves, Gietema, Jourik A., Bang, Yung-Jue, Mileshkin, Linda R., Hirte, Hal W., Higgins, Brian, Blotner, Steven, Nichols, Gwen L., Chen, Lin Chi, Petry, Claire, Yang, Qi Joy, Schmitt, Christophe, Jamois, Candice, Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541972/
https://www.ncbi.nlm.nih.gov/pubmed/34180037
http://dx.doi.org/10.1007/s10637-021-01141-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541972/
https://www.ncbi.nlm.nih.gov/pubmed/34180037
http://dx.doi.org/10.1007/s10637-021-01141-2

Ejemplares similares